AML | Clinician Connection

Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management

Overview

While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatment option. This real-world, case-based program will provide a format for community hematology-oncologists to hear current updates on the latest targeted therapies in AML and engage in pointed, practical discussions on how to best integrate these data into current and local AML treatment paradigms.

Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship:

Amir Fathi - Consulting Fee (e.g., Advisory Board): BMS, Servier, Astellas, Mablytics, Abbvie, Ipsen, Genentech, PureTech, Forma, Daiichi Sankyo, Pfizer, Rigel, Autolus, Amgen, Takeda, Orum, Menarini, Remix, Gilead, AstraZeneca, Syndax, Schrodinger, Prelude Contracted Research (Principal Investigators must provide information, even if received by the institution): Abbvie, Servier, BMS

Courtney DiNardo - Consulting Fee (e.g., Advisory Board):Abbvie, Astellas, AstraZeneca, Daiichi Sankyo, GenMab, GSK, Remix, Rigel, Schrodinger, Servier Contracted Research (Principal Investigators must provide information, even if received by the institution):Abbvie, Astex, BMS, Jazz, Foghorn, Schrodinger, Servier

Brian Jonas - Consulting Fee (e.g., Advisory Board):AbbVie, BMS, Daiichi Sankyo, Gilead, GlycoMimetics, Khmer, Kura, Rigel, Schrödinger, Syndas, Treadwell Contracted Research (Principal Investigators must provide information, even if received by the institution):AbbVie, Amgen, Aptose, AROG, Biomea, BMS, Celgene, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, Treadwell Other (Describe):Protocol steering Committee -GlycoMimetics; Data Monitoring Committee -Gilead; Travel Reimbursement -Rigel The planners and managershave the following relevant financial relationships with ineligible companies:

The planners and managers at Global Education Group have no relevant financial relationships to disclose. The planners and managers at Iridium have no relevant financial relationships to disclose.

Target Audience:

This educational program is directed toward community-based medical oncologists, hematologic oncologists, hematologists, hematopathologists, BMT specialists, NP/PAs, nurses, and pharmacists, other healthcare professionals involved in the treatment of AML.

Learning Objectives:

Upon completion of this educational activity, participants will be able to:

- DISCUSS the impact of molecular testing, risk stratification, and measurable residual disease (MRD) on treatment selection and personalization in patients with AML

-UTILIZE trial evidence and guideline-based recommendations concerning targeted therapies to manage AML case scenarios typically encountered in community settings

- DEVELOP effective strategies to monitor for and manage treatment-related toxicities in patients with AML.

Accreditation and Credit Designation Statements:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium.Global is accredited by the ACCME to provide continuing medical education for physicians.Physician Credit Designation Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Continuing Education Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours including 0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. Pharmacist Accreditation Statement Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.Credit Designation Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number -0530-9999-24-032-H01-P )This is a knowledge-based activity. Global Contact Information For information about the accreditation of this program, please contact Global at 303-395-1782 orcme@globaleducationgroup.com.

Provider(s)/Educational Partner(s):

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

Commercial Support:

This educational activity is supported by independent educational grants from AbbVie Inc. and Astellas Pharma Global Development, Inc.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information& Refund/Cancellation Policy.

There is no fee for this educational activity.

Disclosure of Unlabeled Use.

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Iridium do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

Publication Dates

Release Date: 09/25/2024

Expiration Date: 09/25/2024

Need more details? Contact us

Reach out to us via email, or through our social media channels.